United Arab Emirates Ministry of Health and Prevention Approves Biomerica's Fortel® Kidney Disease Test for Early Detection of Kidney Damage

Core Insights - Biomerica, Inc. has received approval from the UAE Ministry of Health and Prevention for its Fortel® Kidney Disease (Microalbumin) Test, enabling its sale across the UAE, a region with a high prevalence of chronic kidney disease (CKD) [1][8] - The Fortel® Kidney Disease Test is a rapid diagnostic tool that provides results in 10 minutes using a urine sample, allowing for early detection of kidney disease, particularly in high-risk populations [2][4] - CKD is a significant global public health issue, with over 80% of at-risk patients undiagnosed, and is projected to be the 5th leading cause of years of life lost globally by 2040 [2][4] Company Overview - Biomerica is a global biomedical technology company focused on developing advanced diagnostic and therapeutic products, particularly for gastrointestinal and inflammatory diseases [7] - The company aims to enhance health outcomes while reducing healthcare costs through its innovative diagnostic solutions [7][6] - Biomerica has established partnerships with distributors and healthcare providers in the UAE to ensure the availability of the Fortel® Kidney Disease Test across the country [5] Market Context - In the UAE, diabetes and hypertension are major risk factors for CKD, with over 12% of adults living with diabetes and an estimated 29% to 35% of the population having hypertension [4] - The approval of the Fortel® Kidney Disease Test addresses a critical need for preventative healthcare in a region where these conditions are prevalent [5][8] - Early detection through the Fortel® test can lead to timely interventions, potentially reducing the economic burden associated with CKD progression [3]